Answers are grounded in this paper and cite their sources.
We conclude that it is possible to prevent CRS by using "all-in-one" GMCSF-knockout CAR T-cells. This approach may eliminate the need for anti-CRS treatment and may improve the overall safety of CAR T-cell therapies for cancer patients.
No takes yet. Share an insight, caveat, or question.
Sachdeva et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: